Ann: Opyl - Investor presentation introducing Opin, page-3

This slide demonstrates the immense market size.

Again, if toying with any of the other platforms in existence for finding worldwide clinical trials, they do a terrible job at satisfying a customer's search queries/ needs.

The thing that excites me here is that Opyl possesses the marketing knowledge required to drive patients to their platform at a low cost per patient (i.e. via their paid social media marketing channels/ expertise), and simultaneously have the ability to then convert these customers through a site that offers a better user experience. When you consider those + the 44bn USD market they're operating within, the current, low, 15mln AUD valuation is unbelievably low.